Ontology type: schema:ScholarlyArticle
2018-12-03
AUTHORSTakayoshi Tachibana, Satoshi Koyama, Taiki Andou, Yasufumi Ishiyama, Masatsugu Tanaka, Hideaki Nakajima, Heiwa Kanamori
ABSTRACTA single-center retrospective study was performed with consecutive patients who received salvage therapy using ponatinib for the aim of allogeneic hematopoietic cell transplantation (HCT) for relapsed or refractory Ph-leukemia between January 2017 and July 2018. A total of ten patients—seven with Ph-acute lymphoblastic leukemia (ALL) and three with chronic phase (CP)/accelerated phase chronic myeloid leukemia (CML)—were eligible. Eight patients had a history of a single tyrosine kinase inhibitor (TKI) use prior to ponatinib. Any mutation of the tyrosine kinase domain was detected in eight patients, including seven of T315I. The median dose of ponatinib was 15 mg with a median duration of 7 weeks (range 4–23 weeks). The median duration from the start of ponatinib to HCT was 54 days (range 35–175 days). Hematological remission was obtained in five Ph-ALL patients. Maintenance therapy of ponatinib was applied to five patients. No vascular occlusion event has occurred over this series of treatments. Salvage therapy with low-dose ponatinib appears to be safe and effective in patients with relapsed or refractory Ph-leukemia, which may immediately bridge to HCT. More... »
PAGES162-168
http://scigraph.springernature.com/pub.10.1007/s12185-018-02571-0
DOIhttp://dx.doi.org/10.1007/s12185-018-02571-0
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1110344846
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/30511314
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Allografts",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hematopoietic Stem Cell Transplantation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Imidazoles",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Induction Chemotherapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Maintenance Chemotherapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Philadelphia Chromosome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Protein Kinase Inhibitors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pyridazines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Salvage Therapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.414944.8",
"name": [
"Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Tachibana",
"givenName": "Takayoshi",
"id": "sg:person.01074653417.74",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074653417.74"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.414944.8",
"name": [
"Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Koyama",
"givenName": "Satoshi",
"id": "sg:person.01247710606.12",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247710606.12"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.414944.8",
"name": [
"Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Andou",
"givenName": "Taiki",
"id": "sg:person.07656342421.67",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07656342421.67"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.414944.8",
"name": [
"Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Ishiyama",
"givenName": "Yasufumi",
"id": "sg:person.01362612150.73",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362612150.73"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.414944.8",
"name": [
"Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Tanaka",
"givenName": "Masatsugu",
"id": "sg:person.01171141246.33",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171141246.33"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology and Clinical Immunology, School of Medicine, Yokohama City University, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.268441.d",
"name": [
"Department of Hematology and Clinical Immunology, School of Medicine, Yokohama City University, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Nakajima",
"givenName": "Hideaki",
"id": "sg:person.010061552415.35",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010061552415.35"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.414944.8",
"name": [
"Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Kanamori",
"givenName": "Heiwa",
"id": "sg:person.01060176576.11",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060176576.11"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s40261-018-0623-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1100557119",
"https://doi.org/10.1007/s40261-018-0623-7"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bmt.2015.217",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1013878219",
"https://doi.org/10.1038/bmt.2015.217"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12185-017-2238-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1085069121",
"https://doi.org/10.1007/s12185-017-2238-9"
],
"type": "CreativeWork"
}
],
"datePublished": "2018-12-03",
"datePublishedReg": "2018-12-03",
"description": "A single-center retrospective study was performed with consecutive patients who received salvage therapy using ponatinib for the aim of allogeneic hematopoietic cell transplantation (HCT) for relapsed or refractory Ph-leukemia between January 2017 and July 2018. A total of ten patients\u2014seven with Ph-acute lymphoblastic leukemia (ALL) and three with chronic phase (CP)/accelerated phase chronic myeloid leukemia (CML)\u2014were eligible. Eight patients had a history of a single tyrosine kinase inhibitor (TKI) use prior to ponatinib. Any mutation of the tyrosine kinase domain was detected in eight patients, including seven of T315I. The median dose of ponatinib was 15\u00a0mg with a median duration of 7\u00a0weeks (range 4\u201323\u00a0weeks). The median duration from the start of ponatinib to HCT was 54\u00a0days (range 35\u2013175\u00a0days). Hematological remission was obtained in five Ph-ALL patients. Maintenance therapy of ponatinib was applied to five patients. No vascular occlusion event has occurred over this series of treatments. Salvage therapy with low-dose ponatinib appears to be safe and effective in patients with relapsed or refractory Ph-leukemia, which may immediately bridge to HCT.",
"genre": "article",
"id": "sg:pub.10.1007/s12185-018-02571-0",
"inLanguage": "en",
"isAccessibleForFree": false,
"isFundedItemOf": [
{
"id": "sg:grant.6835407",
"type": "MonetaryGrant"
}
],
"isPartOf": [
{
"id": "sg:journal.1076985",
"issn": [
"0925-5710",
"1865-3774"
],
"name": "International Journal of Hematology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "2",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "109"
}
],
"keywords": [
"hematopoietic cell transplantation",
"tyrosine kinase inhibitors",
"Ph-leukemia",
"median duration",
"chronic phase",
"cell transplantation",
"refractory Philadelphia chromosome-positive leukemias",
"single-center retrospective study",
"allogeneic hematopoietic cell transplantation",
"phase chronic myeloid leukemia",
"Philadelphia chromosome-positive leukemia",
"chronic myeloid leukemia",
"patients seven",
"salvage therapy",
"maintenance therapy",
"median dose",
"hematological remission",
"consecutive patients",
"retrospective study",
"lymphoblastic leukemia",
"myeloid leukemia",
"patients",
"ponatinib",
"therapy",
"tyrosine kinase domain",
"kinase inhibitors",
"leukemia",
"series of treatments",
"transplantation",
"duration",
"remission",
"T315I.",
"salvage",
"dose",
"weeks",
"treatment",
"total",
"inhibitors",
"kinase domain",
"occlusion events",
"days",
"aim",
"mutations",
"history",
"study",
"start",
"events",
"series",
"phase",
"pH",
"domain"
],
"name": "Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia",
"pagination": "162-168",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1110344846"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s12185-018-02571-0"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"30511314"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s12185-018-02571-0",
"https://app.dimensions.ai/details/publication/pub.1110344846"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:35",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_775.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s12185-018-02571-0"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-018-02571-0'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-018-02571-0'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-018-02571-0'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-018-02571-0'
This table displays all metadata directly associated to this object as RDF triples.
244 TRIPLES
22 PREDICATES
98 URIs
87 LITERALS
25 BLANK NODES